Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 601–700 of 809
Mancini, G. B. J., Ryomoto, A., Ruel, I. L., Iatan, I., Raal, F. J., Santos, R. D., Chacra, A. P. M., Hegele, R. A., Kennedy, B. A., Brunham, L. R., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120590 · Cited by 4
Self-citationMaligłówka, M., Sojka, A., Dec, A., Okopień, B., & Bułdak, Ł. (2025) · Endokrynologia Polska · doi:10.5603/ep.108425 · Cited by 1
ESC-Leitlinien-Update 2025 zur Dyslipidämie: Neue Empfehlungen für die Praxis
Hohneck, A. L., & Weingärtner, O. (2025) · Herz · doi:10.1007/s00059-025-05354-6 · Cited by 2
Lipoprotein(a) and cardiovascular risk: A roadmap for patient management
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i3.113 · Cited by 1
“…angiopoietin-like protein 3 (ANGPTL3) and thereby increases the lipolytic activity of endothelial lipases, promoting the catabolism of apoB-containing lipoproteins, is effective in reducing LDL-C levels in patients with HoFH, who do not express hepatic LDLR, but does not affect Lp(a) levels [124].”
Brisson, D., Wiegman, A., Waldron, A., Kainth, P., Raal, F. J., & Gaudet, D. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101395 · Cited by 2
“It was approved as an add-on treatment to other LLTs for HoFH patients, based on results of the pivotal phase 3 ELIPSE-HoFH clinical trial (Evi-nacumab LIPid StudiEs in Patients With HoFH) [9].”
Self-citationMeghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1
Raal, F. J., Greber‐Platzer, S., Reeskamp, L. F., Iannuzzo, G., Rosenson, R. S., Saheb, S., Stefanutti, C., Stroes, E. S. G., Bruckert, É., Waldron, A., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120657 · Cited by 2
Self-citationThe 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications
Bonanni, L., Cutolo, A., & Ferri, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07855-w · Cited by 2
“Evinacumab, finally, finds its place in patients with severe forms of dyslipidemia, particularly homozygous familial hypercholesterolemia, where the response to traditional therapies is often insufficient [ 17].”
Hou, Y., Zhang, X., Sun, X., Qin, Q., Jia, M., Su, X., & Chen, Y. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.324122 · Cited by 1
Krishnamurthy, S. S., Buzatto, A. Z., Campkin, C., Müller, H.-P., Wiesner, D., Weishaupt, J. H., Klose, V., Wiesenfarth, M., Elmas, Z., Herrmann, C., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04749-4 · Cited by 2
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 2
“The phase 3 ELIPSE HoFH (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia) trial evaluated evinacumab in patients with HoFH on multiple lipid-lowering therapies and LDL-C was reduced by a mean of 49% compared to placebo [145].”
Shishikura, D., Harada-Shiba, M., Michikura, M., Sakaguchi, K., Kusumoto, H. K., Fujioka, S., Fujisaka, T., Kanzaki, Y., & Morita, H. M. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65959 · Cited by 1
“Another is evinacumab 24) , an anti-ANGPTL3 antibody in a new therapeutic class that is also independent of LDL receptor activity.”
Li, Z., Ye, L., Li, J., Wang, Y., & Yang, J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1836134 · Cited by 1
Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels
Hegele, R. A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671686 · Cited by 2
“Evinacumab, a fully human monoclonal antibody that binds circulating ANGPTL3, provided the first clinical proof-of-concept for therapeutic ANGPTL3 inhibition [22,23].”
In vivo base editing of Asgr1 reduces blood lipids in mice
Agrahari, G., Nguyen, N. T. K., Li, M., Zhang, C., Xu, J., Zhang, J., Chen, Y. E., & Han, R. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.020 · Cited by 1
Myśliwiec, A., Leksa, D., Bartusik‐Aebisher, D., & Aebisher, D. (2026) · Journal of Applied Biomedicine · doi:10.32725/jab.2026.007 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 2
Hou, Y., Luo, Y., Chen, J., Shang, X., Chang, Y., Zhang, X., Ding, Y., Zhao, W., Ding, C., Feng, X., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.036 · Cited by 1
Longer-term efficacy and safety of zodasiran in patients with mixed hyperlipidaemia
Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., Leeper, N. J., Zhou, R., Aiyer, L., Hellawell, J. L., & Watts, G. F. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag376 · Cited by 1
Self-citationWiggins, B. S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001132 · Cited by 2
Jindal, I., & Wang, X. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01063-1 · Cited by 1
“These cardioprotective features of natural ANGPTL3 deficiency have stimulated research interest in inhibiting ANGPTL3’s function, paving way for the recent FDA approval of evinacumab, an anti-ANGPTL3 monoclonal antibody [21].”
BackgroundLipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development
Polychronopoulos, G., Kostourou, D.-T., & Τζιόμαλος, Κ. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2179480 · Cited by 1
“Adverse event rates did not differ between the evinacumab and placebo groups [10].”
BackgroundInfluentialCatapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00013-3 · Cited by 2
Familial hypercholesterolemia with special focus on Japan
Kobayashi, J., Minamizuka, T., Tada, H., & Yokote, K. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117847 · Cited by 1
Tada, H., Kojima, N., Kawashiri, M., & Takamura, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29924 · Cited by 1
“Notably, most of these molecules are now therapeutic targets for LDL-lowering based on these so-called “ human-knockout findings [3 – 6].”
BackgroundPharmacotherapies for Cardiovascular Disease Prevention
Ballard‐Hernandez, J., & Irwin, C. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_14 · Cited by 1
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Sciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
“…with familial hypercholesterolemia in the Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia (ELIPSE HoFH) Trial [81] or in patients with refractory hypercholesterolemia [42] despite optimal medical therapy (including statins, ezetimibe, and PCSK9i).”
Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia
Arora, S., Banerjee, S., George, A., Bala, A., Thingnam, S. K. S., Rohit, M. K., & Dayal, D. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0506 · Cited by 1
Xu, Y., He, H., & Li, H. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41705 · Cited by 1
“Phase 2 and 3 clinical trials are currently ongoing for evinacumab, a monoclonal antibody designed for humans that specifically targets angiopoietin-like protein 3 [16].”
Safely lowering triglycerides through ANGPTL4 inhibition
Wulff, A. B. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00988-2 · Cited by 1
ANGPTL3 inhibition lowers LDL-C levels in FH
Fernández-Ruíz, I. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00441-z · Cited by 1
Gao, M., Yu, W., Hu, H., Liu, H., Fan, K.-J., Gu, C., Wang, L., & Yu, Y. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.535949 · Cited by 1
“Therefore, evinacumab, an inhibitor of angiopoietin-like protein 3, could be added to the treatment regimen to reduce this patient’s LDL-C independent of the defect in the LDL receptor (15).”
BackgroundKyselák, O., Soška, V., Kovar, J., Tichý, L., Grombiříková, H., Hubacek, J. A., & Freiberger, T. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.04.006 · Cited by 1
Biologic therapy for dyslipidemia
Karásek, D. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.054 · Cited by 2
Homozygous familiar hypercholesterolemia: still a long way to go
Sánchez-Hernández, R. M., & Civeira, F. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02223-6 · Cited by 1
Stock, J. K. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.02.008 · Cited by 2
2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Korean Journal of Medicine · doi:10.3904/kjm.2022.97.6.339 · Cited by 1
Therapies for Lowering Low-Density Lipoprotein Cholesterol
Patni, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-24113-0_6 · Cited by 1
Application of approved and marketed products of monoclonal antibody therapies
Elkordy, A., Elsayed, M., Al-Abdulrazag, S. B., & Zarara, Z. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823365-8.00006-2 · Cited by 1
Clinical impact of genetic testing for lipid disorders
Muzurović, E. M., Borozan, S., & Rizzo, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001133 · Cited by 1
Ангиопоэтиноподобный белок 3 типа – новая мишень гиполипидемической терапии
Помогайбо, Б. В., & Евгеньевич, Ф. А. (2022) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2022.02.0002 · Cited by 1
Future Energy Supply, Simulations with Limited Resources
Benichou, L. (2011) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Editorial commentary: Genetics keeps on giving: A possible vaccine for heart disease
Roberts, R. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.02.008 · Cited by 1
Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
Katzmann, J. L., & Laufs, U. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117337 · Cited by 1
USPSTF Recommendation on Screening for Lipid Disorders in Children and Adolescents
McGowan, M. P., Cuchel, M., & Lee, P. C. (2023) · JAMA · doi:10.1001/jama.2023.20443 · Cited by 1
Xie, S., Galimberti, F., Olmastroni, E., Catapano, A. L., & Casula, M. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag230
Perspektiven neuer lipidsenkender Substanzen für die Praxis
Klose, G. (2020) · CardioVasc · doi:10.1007/s15027-020-3424-x
“In einer 24 Wochen-Phase-III-Studie konnte bei 65 Patienten mit hoFH eine gegenüber Placebo 49%ige LDL-C-Senkung gezeigt werden [14].”
BackgroundEmerging New Lipid-Lowering Therapies in the Statin Era
Jang, A. Y., Jo, S., & Koh, K. K. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e5
Guideline recommendations, clinical trial data, and new and emerging therapies
Lindsley, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88607 · Cited by 1
Neue Therapieansätze in der LDL-Cholesterin-Absenkung?
Schettler, V. J. J. (2021) · Dialyse aktuell · doi:10.1055/a-1401-3142
“[18] Raal FJ, Rosenson RS, Reeskamp LF et al.”
BackgroundRisk factors and pharmacological therapy in patients with vascular disease
Maiolino, G., Rossato, M., & Vettor, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822113-6.00021-8 · Cited by 1
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1412728/v1
Evinacumab effektiv bei homozygoter familiärer Hypercholesterinämie
(2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1251-7268
Arvanitis, M., Post, W. S., & Battle, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_3
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1420016/v2
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancersPreprint
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1420016/v3
Medikamentöse Therapie der Fettstoffwechselstörungen im Kindesalter
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_5
Lipidsenkung: neue Substanzen und neue Konzepte
Brandts, J., Verket, M., & Müller‐Wieland, D. (2022) · Herz · doi:10.1007/s00059-022-05133-7
Genetic lipid disorders, the APOE gene and Familial Dysbetalipoproteinemia
Heidemann, B. E. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1408
Klose, G., Gouni‐Berthold, I., & März, W. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00178-9
Klinik, Diagnose und Therapie der familiären Hypercholesterinämie
Klose, G. (2022) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-022-1994-5
Harnessing AI and Genomics to Accelerate Drug Discovery
Feizi, A., & Gutierrez, J. M. (2022) · Future of business and finance · doi:10.1007/978-3-030-99838-7_5 · Cited by 1
Alieva, A. S., Usova, E., & Reutova, O. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i2.14
[Advances in diagnosis and treatment of familial hypercholesterolemia].
Zheng, H., Jiang, S., & Li, L. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.01.22
Bambauer, R., Schiel, R., & Salgado, O. S. (2023) · British journal of healthcare and medical research · doi:10.14738/bjhmr.102.14266
“Alcohol abuse, cholelithiasis, hyperlipidemia and other specific factors are the important causes of AP [18, 107].”
BackgroundHomozygous Familial Hypercholesterolemia
Raal, F. J. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100324
Self-citationEmerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_8
Auf Umwegen in die Lipidambulanz
Stach, K., Schaarschmidt, M., & Adam, R. (2021) · CardioVasc · doi:10.1007/s15027-021-3572-7
The future is now: promising therapies
Ruiz, Á. J., Campo, R., Román-Gonzaléz, A., & Santos, R. D. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000215
Çafka, M. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.52.008278
(2023) · Journal of Clinical & Experimental Immunology · doi:10.33140/jcei.08.03.04
RNA interference-based therapies for atherosclerosis: Recent advances and future prospects
Parsamanesh, N., Poudineh, M., Siami, H., Butler, A. E., Almahmeed, W. A., & Sahebkar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.009 · Cited by 3
Prise en charge des patients avec hypercholestérolémie familiale
Perregaux, J.-F., & Gallo, A. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.001
VI. Atherosclerotic Cardiovascular Disease from the Perspective of Genetics
Tada, H. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.194
Statine: Nebenwirkungen – alternative Therapieoptionen
Makhmudova, U., & Weingärtner, O. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00669-w · Cited by 1
“Der monoklonale Antikörper Evinacumab zeigte in Phase-III-Studien eine 47%ige Reduktion des LDL-C bei Patienten mit homozygoter familiärer Hypercholesterinämie (HoFH) [80].”
Larouche, M., & Gaudet, D. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.009
Self-citationA Family with Familial Hypobetalipoproteinemia Caused by a c.1468C>T in APOB
Tada, H., Kojima, N., Nomura, A., & Takamura, M. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3033-23
Tani, R., Matsunaga, K., Toda, Y., Inoue, T., Fu, H. Y., & Minamino, T. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8537
A narrative review of treatment modalities for familial hypercholesterolemia
Samprokatsidis, G., Antza, C., Frangou, D., & Kotsis, V. (2023) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1054
Tran, T. T. M., Tran, B. T., Nguyen, M. T., Hong, D. D. T., Nguyen, V. T., Nguyen, N. B. K., Pham, T. T. H., Ho, U. P., Vo, H. L., Luong, T. T. T., et al. (2023) · Tạp chí Y Dược Huế · doi:10.34071/jmp.2023.6.1
Guan, B., Wang, A., & Xu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23930438
Supravalvular Aortic Stenosis in Homozygous Familial Hypercholesterolemia
Eisenberg, S. D., Gold, D., Mehta, P. K., Leshnower, B. G., & Sperling, L. S. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102342
CADTH (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.872
APOC3 inhibitors and their effects to hypertriglyceridemia and atherosclerosis
Plengpanich, W. (2024) · Chulalongkorn Medical Journal · doi:10.56808/2673-060x.5391
Inhibitors ANGPTL3 and their effects to hyperlipidemia and atherosclerosis
Plengpanich, W. (2024) · Chulalongkorn Medical Journal · doi:10.56808/2673-060x.5385
Familial Hypercholesterolemia presenting with Acute Coronary Syndrome (NSTEMI)Preprint
Chaudhary, G. K., Pradhan, A. K., Roy, S., Shukla, A., Chandra, S., & Hasibuzzaman, M. A. (2024) · doi:10.22541/au.171717662.27987386/v1
张, 卓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451662
Enhancing Cardiovascular Risk Assessment with Coronary Artery Calcium Scoring: A Comprehensive Study
Quddus, R. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24523123906
Novel approaches to treat primary hyperlipidemia
Vachhani, J. M., & Tirgar, P. (2024) · American Journal of Biopharmacy and Pharmaceutical Sciences · doi:10.25259/ajbps_7_2024
Ieki, H., Ito, K., Zhang, S., Koyama, S., Kjellberg, M., Yoshida, H., Kurosawa, R., Matsunaga, H., Miyazawa, K., Enzan, N., et al. (2026) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005341
Kalsi, H., Singla, A., Kaur, S., Verma, A., Woldehana, N. A., Rustagi, S., & Singh, M. P. (2024) · Clinical Case Reports · doi:10.1002/ccr3.9492
Taradeh, M. (2023) · theses.fr (ABES) · doi:10.70675/8cb53537z2270z4c15zb7b0za5a5fecc4fe3 · Cited by 2
Abdelkader, C., Madani, Z., Zohra, H., Pucci, L., & Yahia, D. A. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n9-321
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752 · Cited by 2
“…Patients With Homozygous Familial Hypercholesterolemia) phase 3 trial in patients with homozygous familial hypercholesterolemia (FH), showed evinacumab 15 mg/kg intravenous every 4 weeks reduced LDL-C by a mean of 49% compared with placebo after 24 weeks regardless of the function of the LDLR [64].”
Yang, Z., Xiao, W., Zhuang, Z., Zhan, S., Wang, M., Wu, Y., Huang, T., & Li, R. (2025) · PubMed Central · doi:10.6133/apjcn.202502_34(1).0004 · Cited by 1
“14 Since the causal effect of dyslipidemia in psoriasis has been demonstrated, 10 evinacumab may be a promising adjuvant therapy for managing psoriasis via ANGPTL3 inhibition and should be carefully investigated.”
Ross, L. J. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2024.11.011
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100739 · Cited by 1
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.